QUALITATIVE EXPLORATION OF THE REAL-WORLD EXPERIENCES OF MEN RECEIVING OR REFUSING CHEMOTHERAPY (DOCETAXEL) FOR THE TREATMENT OF METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)

被引：0
|
作者：
Ito, T. [1 ]
Grant, L. [2 ]
Mills, A. [3 ]
Heselwood, A. [3 ]
Gater, A. [2 ]
机构：
[1] Janssen Cilag UK, High Wycombe, Bucks, England
[2] Adelphi Values Ltd, Bollington, Cheshire, England
[3] Adelphi Res UK, Bollington, Cheshire, England
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.295
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN212
引用
收藏
页码：A450 / A450
页数：1
相关论文
共 50 条
  • [21] TEAM Study: Upfront Docetaxel Treatment in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World, Multicenter, Retrospective Analysis
    Pisano, Chiara
    Turco, Fabio
    Arnaudo, Elena
    Fea, Elena
    Vanella, Paola
    Ruatta, Fiorella
    Filippi, Roberto
    Brusa, Federica
    Prati, Veronica
    Vana, Federica
    Mennitto, Alessia
    Cattrini, Carlo
    Vignani, Francesca
    Dionisio, Rossana
    Icardi, Massimiliano
    Guglielmini, Pamela
    Buosi, Roberta
    Stevani, Ilaria
    Vormola, Roberto
    Numico, Gianmauro
    Depetris, Ilaria
    Comandone, Alessandro
    Gennari, Alessandra
    Rossi, Maura
    Airoldi, Mario
    Vellani, Giorgio
    Ortega, Cinzia
    Tucci, Marcello
    Di Maio, Massimo
    Buttigliero, Consuelo
    CLINICAL GENITOURINARY CANCER, 2024, 22 (02) : 56 - 67.e16
  • [22] Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): an Evolving Treatment Paradigm
    Adam B. Weiner
    Oluwarotimi S. Nettey
    Alicia K. Morgans
    Current Treatment Options in Oncology, 2019, 20
  • [23] Underutilization of androgen deprivation therapy (ADT) intensification for the treatment of men with metastatic hormone-sensitive prostate cancer (mHSPC): A systematic review of real-world database studies.
    Raval, Amit D.
    Chen, Stephanie
    Littleton, Natasha
    Constantinovici, Niculae
    Goebell, Peter J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 66 - 66
  • [24] AN INFLECTION POINT IN REAL-WORLD TREATMENT INTENSIFICATION FOR MEN WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) IN THE UNITED STATES (US): RESULTS FROM PATIENT CHART REVIEWS
    Grossman, J.
    Chen, S.
    Goebell, P. J.
    VALUE IN HEALTH, 2024, 27 (06) : S367 - S367
  • [25] Apalutamide toxicity and tolerability: A real-world multicentre experience in metastatic hormone-sensitive prostate cancer (MHSPC) in the United Kingdom (UK).
    Ramamurthy, Sindhu
    Elumalai, Thiraviyam
    Pearson, Rachel
    Bolnykh, Iakov
    Muhammad-Afzal, Tehreem
    Olukiran, Gbenro
    Arora, Ananya
    Bradley, Gay
    Taft, Kate
    Myint, Nayan Lin
    Htike, Ei The
    Ince, Will
    Jiang, Xue Yan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL)
  • [26] Febrile Neutropenia Rates in Men Treated with Docetaxel Chemotherapy for Metastatic Hormone-sensitive Prostate Cancer Reply
    Vicini, F.
    Shah, C.
    Mantz, C.
    CLINICAL ONCOLOGY, 2016, 28 (09) : 612 - 613
  • [27] Effectiveness of Adding Docetaxel to Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer in Korean Real-World Practice
    Park, Kwonoh
    Kim, Jin Young
    Park, Inkeun
    Shin, Seong Hoon
    Lee, Hyo Jin
    Lee, Jae Lyun
    YONSEI MEDICAL JOURNAL, 2023, 64 (02) : 86 - 93
  • [28] Is Docetaxel Chemotherapy a New Standard of Care for Metastatic Hormone-Sensitive Prostate Cancer?
    Liaw, Bobby C.
    Oh, William K.
    AMERICAN JOURNAL OF HEMATOLOGY-ONCOLOGY, 2015, 11 (09) : 17 - 20
  • [29] Docetaxel Treatment for Metastatic Hormone-sensitive Prostate Cancer in Daily Practice
    de Groot, Ietsen
    Brinkman, Ithamar
    Luijendijk-de Bruin, Daphne
    Poort, Sharon
    van Rooijen, Johan M.
    EUROPEAN UROLOGY OPEN SCIENCE, 2021, 33 : 48 - 55
  • [30] Use of abiraterone for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
    Cathomas, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 130 - 130
12345